• Investing Insights & Exclusive Offers → Get Our FREE “Market Brief”
    Sign-up for our free weekly newsletter. Get unparalleled investing insights and exclusive Summer Sale discounts on Hedgeye research.

    Disclaimer: By joining our email marketing list you agree to receive marketing emails from Hedgeye. You may unsubscribe at any time by clicking the unsubscribe link in one of the emails. Use of Hedgeye and any other products available through hedgeye.com are subject to our Terms Of Service and Privacy Policy

Takeaway: Join us next week on Tuesday, July 30 at 2PM ET when we will break down the status of major provisions in House and Senate bills

State of Play | Congress' Ambitious Drug Price Agenda

Tuesday, July 30 @2PM CT

Add to Outlook Calendar

Healthcare & Health Policy Subscribers: CLICK HERE for event details (includes video link, materials link and dial-in).

For an uncooperative browser cut and paste link: https://app.hedgeye.com/feed_items/76718

  

First it was by July 4th. Then it was by August recess. Now the best case ETA for floor action on Congress' complex and far reaching drug price legislation is after the Labor Day holiday. The new schedule allows the Senate at least to live up to its reputation as the World's Most Deliberative Body. It also gives a raft of special interests an opportunity to bring all their lobbying acumen to bear on Members of Congress and the White House. To keep the best track of the sausage making, we will lay out the areas of agreement and disagreement and likely compromises that may emerge when September comes.

Highlights:

  • Revisiting the Rebate Rule
  • The Future of the International Pricing Index proposed rule, if any
  • New disclosure requirement for PBMs, health plans and others
  • Price "controls" of Medicare drugs
  • Commercial rebate pass-through
  • Commercial v Medicaid spread pricing prohibition
  • And more.

Have a topic you want to covered? Send it in.

Emily Evans
Managing Director – Health Policy



Twitter
LinkedIn

Thomas Tobin
Managing Director


Twitter
LinkedIn